The patient sample was treated with peg (polyethylene glycol 6000) and the result was 22.05 u/ml.Siemens healthcare diagnostics is investigating the cause of the discordant ca19-9 results.The ifu states in the limitations section: "note: do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals.Additionally, elevated levels of ca 19-9 can be observed in patients with nonmalignant diseases.Measurements of ca 19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.Warning: do not use the advia centaur cp ca 19-9 assay as a screening test or for diagnosis.Do not predict disease recurrence solely on levels of advia centaur cp ca 19-9.Normal levels of advia centaur cp ca 19-9 do not always preclude the presence of disease.The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.Therefore, it is important to use assay specific values to evaluate quality control results." mdr 1219913-2019-00235 (repeat result) was filed for the same event.
|
Siemens filed the initial mdr 1219913-2019-00234 on november 13, 2019.12/10/2019 additional information: the initial issue was reported as a discordant patient result for ca 19-9 between the advia centaur cp and an alternate method.Siemens cannot definitively determine the cause of this discrepant result.There is a possibility that this represents a heterophilic (hama) interference which we know can occur in any immunoassay despite the presence of blocker substances in the advia centaur ca19-9.Per the advia centaur cp ca 19-9 instructions for use limitation section: "heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be observed.Additional information may be required for diagnosis." the quality control was in range and no issues were noted with other patient samples indicating that the instrument and reagents were performing acceptably.Repeat of the same sample yielded expected results.Return of the patient sample is not possible because it has been used up.A potential product issue has not been identified.The instrument is performing within specifications.No further evaluation of the device is required.Mdr 1219913-2019-00235 supplemental report 1 was filed for the same event.
|